Research ArticleAccepted Article
Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic
Jérôme Avouac, Anna Molto, Camélia Frantz, Sarah Wanono, Elise Descamps, Olivier Fogel, Alice Combier, Lucile Poiroux, Corinne Miceli-Richard and Yannick Allanore
The Journal of Rheumatology June 2022, jrheum.220073; DOI: https://doi.org/10.3899/jrheum.220073
Jérôme Avouac
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Anna Molto
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Camélia Frantz
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Sarah Wanono
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Elise Descamps
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Olivier Fogel
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Alice Combier
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Lucile Poiroux
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Corinne Miceli-Richard
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
Yannick Allanore
Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France. Conflict of interest: JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche- Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi; AM: Honoraria: Abbvie, Biogen, BMS, Gilead, Janssen, MSD, Novartis, Lilly, Pfizer, UCB. Research Grants: Pfizer and UCB. Financial Support: This work has received a research grant from Fresenius Kabi. Corresponding author: Pr. Jérôme Avouac Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France. e-mail: jerome.avouac@aphp.fr.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic
Jérôme Avouac, Anna Molto, Camélia Frantz, Sarah Wanono, Elise Descamps, Olivier Fogel, Alice Combier, Lucile Poiroux, Corinne Miceli-Richard, Yannick Allanore
The Journal of Rheumatology Jun 2022, jrheum.220073; DOI: 10.3899/jrheum.220073
Accepted manuscript
Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic
Jérôme Avouac, Anna Molto, Camélia Frantz, Sarah Wanono, Elise Descamps, Olivier Fogel, Alice Combier, Lucile Poiroux, Corinne Miceli-Richard, Yannick Allanore
The Journal of Rheumatology Jun 2022, jrheum.220073; DOI: 10.3899/jrheum.220073